As a general rule, when you hear about a tiny biotech “partnering” with a Big Pharma giant to market a drug, it’s the smaller company that’s doing all the work — and the larger company that’s providing the marketing heft (and the money to market the drug). But this news is a bit different. In fact, it’s the exact opposite of what you’d ordinarily expect.Nabriva Therapeutics (NBRV), a microcap biotech based in Dublin, Ireland, announced Thursday that it will partner up with American Big Pharma giant Merck (MRK) to market Merck’s “SIVEXTRO” antibiotic for treating acute bacterial skin and skin …read more
Source:: Yahoo Finance
